Resources

This is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs with each rotavirus vaccine product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

This factsheet focuses on the development of BABE—a low-cost bubble continuous positive airway pressure (bCPAP) device with oxygen blenders to help babies with respiratory distress syndrome. BABE is designed to provide bCPAP therapy to preterm newborns without requiring a power source (i.e., electricity or battery) or medical-grade compressed air.

Part 1 of “Rethinking the future of maternal and child survival in Africa in a changing aid landscape,” the newest edition to our Africa regional MNCH advocacy dialogues series, was held on June 26, 2025, featuring a moderated discussion with panelists from PATH, UNICEF, Africa Union Commission, Umzanyana Birth Services, Reproductive Health Division, and MSD for Mothers. The resource below is one of the presentations from the webinar. In the coming weeks we will share the recording for the webinar as well.

According to the World Health Organization, medical oxygen is one of the key essential medicines required for multiple health conditions, including asthma, heart failure, and various newborn complications. Over the last decade, the Ugandan government has worked to improve access to medical oxygen. The National Scale Up of Medical Oxygen Implementation Plan (2018–2022), launched in 2019, guided this progress, which included increasing manufacturing capacity and installing oxygen plants at referral hospitals.

Immunization is one of the most impactful and cost-effective public health interventions available, saving up to 4 million lives every year, according to the World Health Organization (WHO). In addition to its direct impact on the health of populations, immunization brings added value by reducing the burden of disease on individuals, families, and communities.